Ultragenyx agrees to sell rare pediatric disease priority review voucher for $210 million
Bitget2026/10/07 12:32Ultragenyx entered a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for USD 210 million. The voucher was awarded on FDA clearance of GENGLYCOS (DTX401) for glycogen storage disease type Ia. Proceeds are expected to provide non-dilutive funding for pipeline development, supporting the company’s profitability plans. Closing depends on customary conditions, including expiration of the Hart-Scott-Rodino waiting period. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070830PRIMZONEFULLFEED9841089) on October 07, 2026, and is solely responsible for the information contained therein.
- Ultragenyx entered a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for USD 210 million.
- The voucher was awarded on FDA clearance of GENGLYCOS (DTX401) for glycogen storage disease type Ia.
- Proceeds are expected to provide non-dilutive funding for pipeline development, supporting the company’s profitability plans.
- Closing depends on customary conditions, including expiration of the Hart-Scott-Rodino waiting period.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
“Old ginger is spicier”! Outperforming semiconductors and debt panic, post-Buffett era Berkshire (BRK.A.US) hits another record high
Berkshire Hathaway Class B shares rose as much as 3.2% to $543.06 intraday on Wednesday, marking a new all-time high since May 2, 2025. After Buffett announced his resignation a year ago, the stock price fell for several months; now, the market has set a new record high, representing its first valuation of the "post-Buffett era."
BIS closed-door meeting sends message to Wall Street: No signs of “systemic risks” from AI
At a closed-door Wall Street meeting with ticket prices starting at $7,500 and no media access, U.S. Treasury Secretary Bessent stated that she does not see any “systemic issues” with AI, refuting bubble concerns by saying, “This isn’t Pets.com.” She added that those betting on AI are “the smartest people in the world.” These comments come at a sensitive time as AI stocks have seen multiple bouts of volatility recently.
Tail risks before the US midterm elections
Crypto prices
More
